Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.53 |
| ▸ | CDC7 | O00311 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | INSR | P06213 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | TOP2A | P11388 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 6/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.44 |
| ▸ | PAK4 | O96013 | 3/20 | 0.44 |
| ▸ | PIM1 | P11309 | 3/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.44 |
| ▸ | CLK2 | P49760 | 3/20 | 0.44 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | PRKACA | P17612 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6398272 | 0.86 | IRAK4 (0.47) | IRAK4CDC7KDRINSRCSF1R | |
| SCHEMBL6402777 | 0.83 | IRAK4 (0.46) | IRAK4CDC7KDRINSRCSF1R | |
| SCHEMBL3286543 | 0.81 | JAK3 (0.50) | IRAK4CDC7KDRPDGFRBPDGFRA | |
| SCHEMBL6395906 | 0.80 | KDR (0.60) | KDRINSRCSF1RPDGFRBPDGFRA | |
| SCHEMBL10242655 | 0.79 | SYK (0.64) | SYK | |
| SCHEMBL6731924 | 0.78 | KDR (0.53) | KDRINSRCSF1RPDGFRBPDGFRA | |
| SCHEMBL6401267 | 0.76 | KDR (0.47) | IRAK4KDRINSRCSF1RPDGFRB | |
| SCHEMBL13896211 | 0.76 | TOP2A (0.53) | IRAK4KDRINSRCSF1RPDGFRB | |
| SCHEMBL6729308 | 0.75 | IRAK4 (0.49) | IRAK4CDC7KDRINSRCSF1R | |
| SCHEMBL6315627 | 0.74 | KDR (0.64) | IRAK4KDRINSRCSF1RPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549645-A1 | 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS | Johnson & Johnson Pharmaceutical Research & Development, Inc. (US) | 2005-07-06 | — | — | EP | claimed |
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | claimed |
| WO-2004031184-A1 | 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. (US) | 2004-04-15 | — | — | WO | claimed |
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | TIE1, KDR, FLT1 | IRAK4 408/4885CDC7 481/4885KDR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.